Vancouver, Canada – July 22, 2026 – Augurex Life Sciences Corp., a leader in autoimmune biomarker diagnostics, today announced the acceptance of three abstracts at the 2026 Association for Diagnostics and Laboratory Medicine 2026 Conference, being held July 26-30, 2026 at the Anaheim Convention Centre in Anaheim, California.
These abstracts highlight Augurex’s innovative research leveraging both 14-3-3eta autoantibodies and the 14-3-3eta protein in the field of autoimmune diseases, including axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA).
The research, to be presented by Dr. Anthony Marotta, PhD, Chair of Augurex’s Clinical and Scientific Advisory Committees, highlights data generated by Augurex in collaboration with leading global key opinion leaders which underscore the potential for SPINEstat® and JOINTstat® to transform how autoimmune diseases are diagnosed and managed.
“We’re honored to share these three abstracts, including one which has been recognized by ADLM with a Best Abstract in Immunology award. This work reflects our continued progress in addressing two persistent challenges in rheumatology: the diagnostic delay in axSpA and the growing population of seronegative rheumatoid arthritis patients who fall outside conventional serology,” said Dr. Marotta. “Together, these findings reinforce 14-3-3eta’s growing role as a diagnostic biomarker platform that helps clinicians reach an earlier, more confident diagnosis.”
Below is the list of accepted abstracts, with links to each:
Poster Presentations
Wednesday, July 29, 2026
Session: Clinical and Diagnostic Immunology
Display Time: 9:30am – 5:00pm Pacific Time
Presentation: 1:30 – 2:30pm Pacific Time
- Anti-14-3-3eta Autoantibodies: A Novel Diagnostic Biomarker that Discriminates Axial Spondyloarthritis from Mechanical Backpain
Abstract: 4216485 | Poster number: B-181 - Authors: Marotta A; Cavill C; Bleakley S; Maksymowych WP; Sengupta R.
- ———
- Winner: Immunology Abstract Award, ADLM Immunology & Infectious Disease (IID) Division
- ePoster Highlight Presentation: July 29, 2026, 12:30 – 1:30pm
- Performance of Anti-14-3-3eta Multiplex Autoantibody Assay in Differentiating Axial Spondyloarthritis from Diseases with Overlapping Symptoms
Abstract: 4216484 | Poster number: B-180 - Authors: Marotta A; Bleakley S; Gui Y; Wichuk S; Maksymowych WP.
- Clinical Utility of the 14-3-3eta Protein in Seronegative Rheumatoid Arthritis
Abstract: 4216486 | Poster number: B-182 - Authors: Marotta A; Bleakley S; Gui Y.
Augurex will also exhibit at the ADLM Clinical Lab Expo, taking place July 28–30, 2026 where the Company will showcase and present SPINEstat® as a finalist for the ADLM Disruptive Technology Award.
For more information or to schedule a meeting with our team during the conference, please reach out to schahal@augurex.com.
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s 14-3-3eta blood test, available as JOINTstat® in Canada and in Great Britain, is an important tool in the diagnosis and management of rheumatoid arthritis. Analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex test, approved as SPINEstat® in Canada and Great Britain, expands Augurex’s portfolio of autoimmune diagnostic solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, which, if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.